2-ethoxy-2-methoxy-propane | 29328-22-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-ethoxy-2-methoxy-propane
• 英文别名: aceton-(ethyl-methyl-acetal)；Aceton-(aethyl-methyl-acetal)；2-Aethoxy-2-methoxy-propan；Aceton-methylethylketal；acetone ethyl methyl ketal；2-Ethoxy-2-methoxypropane
• CAS: 29328-22-1
• 化学式: C₆H₁₄O₂
• 分子量: 118.176
• InChiKey: HXDWMTYIWJLRJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2909199090

反应信息

• 作为产物：
  描述：

  乙醇 、 2-甲氧基丙烯 在 copper(ll) bromide 作用下， 以 乙醚 为溶剂， 以82%的产率得到2-ethoxy-2-methoxy-propane
  参考文献：
  名称：

  Tordeux, M.; Dorme, R.; Wakselman, C., Synthetic Communications, 1983, vol. 13, # 8, p. 629 - 634

  摘要：

  DOI：

文献信息

• Process for Producing Simvastatin
  申请人：Ye Hongping

  公开号：US20090043115A1

  公开（公告）日：2009-02-12

  The present invention discloses a process for producing Simvastatin and intermediate thereof. The present invention uses inexpensive and easily available reagents, its condition is mild, and it leaves out the protective and deprotective steps, which are necessary in prior methods. Compared with prior art, the esterifying condition in 8-position is greatly simplified.

  本发明公开了一种生产辛伐他汀及其中间体的方法。本发明使用廉价且易获得的试剂，其条件温和，并省略了先前方法中必需的保护和去保护步骤。与现有技术相比，8位位置的酯化条件得到了极大简化。
• Process for preparing acetonides
  申请人：——

  公开号：US20020132837A1

  公开（公告）日：2002-09-19

  Acetonides are obtained in a one-step reaction of a carboxylic acid halide, a 1,2-aminoalcohol, and 2-alkoxypropene or 2,2-dialkoxypropane in an ether solvent and in the presence of an inorganic base. Acetonides are also obtained in a two-step reaction scheme in which an acid halide and 1,2-aminoalcohol are reacted in an ether solvent in the presence of LiOH to form a hydroxyamide, which is then reacted with 2-alkoxypropene or 2,2-dialkoxypropane in the presence of acid to form the acetonide. The acetonides resulting from the one-step and two-step protocols can be further reacted with an allylating agent such as an allyl halide in the presence of a strong base to provide the corresponding allyl acetonide. The acetonides and allyl acetonides can serve as intermediates in the production of certain HIV protease inhibitors which are useful for treating HIV infection and AIDS.

  Acetonides是通过在醚溶剂中，在无机碱的存在下，将羧酸卤、1,2-氨基醇和2-烷氧基丙烯或2,2-二烷氧基丙烷进行一步反应而获得的。Acetonides也可以通过两步反应方案获得，其中酸卤和1,2-氨基醇在醚溶剂中在LiOH的存在下反应以形成羟基酰胺，然后在酸的存在下与2-烷氧基丙烯或2,2-二烷氧基丙烷反应以形成缩醛。通过一步和两步方案得到的缩醛可以进一步与烯丙基卤等烯丙基化试剂在强碱的存在下反应，从而得到相应的烯丙基缩醛。这些缩醛和烯丙基缩醛可以作为某些用于治疗HIV感染和艾滋病的HIV蛋白酶抑制剂的生产中间体。
• TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF
  申请人：Seldar Pharma Inc.

  公开号：US20140058100A1

  公开（公告）日：2014-02-27

  To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

  提供一种药物，特别是一种可用作治疗肠易激综合征（IBS）的治疗剂的化合物。发现在4位具有酰胺基团的四氢异喹啉-1-酮衍生物或其药学上可接受的盐具有出色的炸弹素2（BB2）受体拮抗作用。同时发现四氢异喹啉-1-酮衍生物对肠道运动障碍具有很高的有效性。由此可见，本发明的四氢异喹啉-1-酮衍生物可用作与BB2受体相关的疾病，特别是IBS的治疗剂。
• HUVASTATIN AND ITS PREPARATION AND FORMULATION COMPRISING THE HUVASTATIN
  申请人：HUAIBEI HUIKE PHARMACEUTICAL CO., LTD.

  公开号：EP1693360A1

  公开（公告）日：2006-08-23

  The invention relates to statin compounds, and it discloses novel small molecule compounds, i.e., huvastatin, which are classified into I, II, III. The invention also provides the production methods thereof and the formulations comprising the huvastatin as active components. The present compounds can be used at a lower dosage with respect to the existing statin compounds, and also can help to obtain the desired lipid levels of the patents with hyperlipidemia. Huvastatin of the invention has suitable hydrophilicity, stronger potency to reduce lipid levels, good medical effect and lower dose usage.

  本发明涉及他汀类化合物，公开了新型小分子化合物，即赫伐他汀，分为 I、II、III 类。本发明还提供了其生产方法和以胡伐他汀为活性成分的制剂。与现有的他汀类化合物相比，本发明化合物的使用剂量较低，也有助于获得高脂血症患者所需的血脂水平。本发明的赫伐他汀具有合适的亲水性、更强的降脂效力、良好的医疗效果和更低的使用剂量。
• Reppe et al., Justus Liebigs Annalen der Chemie, 1956, vol. 601, p. 81,104
  作者：Reppe et al.

  DOI：——

  日期：——